GSK PLC (LSE:GSK) - Share price

Stock Report


Last Price

Day Change

As of 26/05/2022
07:59:12 BST | GBX
Minimum 15 Minutes Delay.

Last Close1,775.00p
Day Range1,753.80 - 1,785.20
Mkt Cap90.24Bil
52-Wk Range1,215.83 - 1,817.00
Yield %4.28

Share Price

Total Returns 26/05/2022

 Chg (%)  
More ...
GSK PLC6.10 
FTSE 100 TR GBP7.54
More ...
Income Statement
Operating Profit6,292.006,224.006,683.00
Net Profit5,268.006,388.005,096.00
Reported EPS92.60114.1086.60
Balance Sheet
Current Assets18,618.0020,141.0018,652.00
Non Current Assets60,201.0060,184.0060,429.00
Total Assets79,692.0080,431.0079,103.00
Current Liabilities24,050.0022,148.0023,670.00
Total Liabilities61,335.0059,623.0057,761.00
Total Equity18,357.0020,808.0021,342.00
Cash Flow
Operating Cash Flow9,532.0010,096.009,243.00
Net Change in Cash826.00470.00-1,414.00

Regulatory News

DateAuthor Headline
24/11/2020Damien Conover Covid Vaccine Breakthrough: the Morningstar View
Morningstar analyst Damien Conover looks in detail at the latest vaccine developments from AstraZeneca and Pfizer/BioNTech
24/07/2019James Gard Glaxo's Vaccines Division Outperforms
FTSE 100 dividend stalwart posts steady results in the first six months and expects better performance in the second half, during which the joint venture with Pfizer will complete
10/07/2019Emma Simon Dividend Shares to Fund My Retirement
Investor Views: Private investor Gurmit Dhendsa is running his own share portfolio rather than rely on a pension manager
Director Dealings
More ...
22/07/2021PurchaseDr. Hal V Barron19.622,36146,311.00
13/07/2021DDr. Hal V Barron20.222,45049,543.00
13/07/2021DMs. Emma N. Walmsley1,441.972,80040,375.00
12/07/2021DDr. Hal V Barron19.991,08021,584.00

Company Profile

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.


Drug Manufacturers - General


FTSE 100 , FTSE 350 , FTSE All Share , FTSE Eurotop 100 , FTSE Eurotop 300

Next Event 28/07/2022

Half-Yearly Results
More ...
PER (E)17.81
Div Yld (E)4.45
PEG (E)2.02
Op Mrgn0.20
EPS Grwth0.12
More ...
Record Date25/02/2220/05/22
More ...
Non-Executive DirectorMs. Lynn Laverty Elsenhans
Executive Director, Chief Scientific Officer and President, RandDDr. Hal V Barron
Non-Executive DirectorMs. Judy C. Lewent
Non-Executive DirectorDr. Laurie H. Glimcher
Non-Executive Director, ChairmanSir Jonathan Richard Symonds CBE
Non-Executive Director, Senior Independent DirectorMr. Manvinder Singh Banga
Non-Executive DirectorMr. Urs Rohner
Non-Executive DirectorDr. Vivienne Cox, CBE
Non-Executive DirectorMr. Charles A. Bancroft
Company SecretaryMrs. Victoria Anne Whyte
Executive Director, Chief Financial OfficerMr. Iain J Mackay
Executive Director, Chief Executive OfficerMs. Emma N. Walmsley
Non-Executive DirectorDr. Jesse Goodman
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2022 Morningstar. All rights reserved.